How Agent Bots Are Transforming Clinical Trial Access for Gynecologic Cancer Patients Clinical trials are vital for advancing treatments in gynecologic cancers, yet enrollment remains a major challenge—especially among underserved populations. Limited funding, fragmented communication, and the rarity of certain disease subtypes often lead to low accrual and missed opportunities for patients and researchers alike. A new initiative is using AI and chatbot technology to change that.

In collaboration with Botco.ai, a HIPAA-compliant conversational AI platform, a new agent bot-assisted system is being developed to streamline how oncologists and research staff identify and refer patients to relevant clinical trials. By using intelligent logic to evaluate patient-specific factors—such as prior therapies, genetic markers (e.g., BRCA, HRD, HER2), and treatment response—the agent bot provides real-time trial matches and referral pathways.

The agent bot is accessible via mobile browser and SMS, allowing clinicians to quickly screen patients, securely send referral information, and receive updates on trial availability. It also offers a feedback loop that tracks usage and enrollment, helping to continually refine the AI’s accuracy and effectiveness.

This platform is designed to reduce duplication of efforts, increase trial visibility, and improve collaboration among research centers. Most importantly, it aims to boost access for patients who have historically been underrepresented in clinical research, including individuals from non-White and lower socioeconomic backgrounds.

Early implementation goals include improving provider satisfaction and awareness of trial options by 50%, while accelerating patient matching and improving equity in enrollment.

As clinical trials become increasingly personalized and data-driven, agent bot-assisted tools like this one represent a scalable, forward-thinking solution to one of oncology’s most persistent challenges: connecting the right patients to the right trials at the right time.